🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Unresectable Biliary Tract Cancer

Dynamic Prediction Model for Patients with Unresectable Biliary Malignancies Receiving Systemic Chemotherapy Combined with Immunotherapy: a Multicenter, Observational Study NCT06849193n/a2 sites📍 Nanjing📍 Nanjing Zhongda Hospital · Tests: Systemic chemotherapy combined with immunotherapy Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma NCT07780838Phase 21 site📍 Columbus Ohio State University Comprehensive Cancer Center · Tests: Biospecimen Collection, Cisplatin, Computed Tomography, Durvalumab, Gemcitabine A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract Cancers NCT06611345NA1 site📍 Hefei Jiangsu Healthy Life Innovation Medical Technology Co., Ltd · Tests: Tumor Treating Fields, Durvalumab, Gemcitabine, Cisplatin Observational Study Protocol: LIVER-R NCT06252753n/a160 sites📍 Birmingham📍 Mobile📍 Phoenix AstraZeneca · Tests: Durvalumab-based combination therapies in observational study setting, Durvalumab-based combination therapies in observ… Endoscopic Radiofrequency Ablation for Unresectable Cholangiocarcinoma NCT06175845NA9 sites📍 Berlin📍 Bonn📍 Chemnitz Universitätsklinikum Hamburg-Eppendorf · Tests: Intraductal biliary radiofrequency ablation A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer NCT07135544Phase 21 site📍 Wuhan Yongjun Chen · Tests: Adebrelimab combined with the GC regimen and Apatinib Combination Therapy of GCNT and Tislelizumab in Advanced Biliary Tract Cancer NCT06893380n/a1 site📍 Seongnam-si CHA University · Tests: Gemcitabine, Cisplatin, Nab-paclitaxel, and Tislelizumab. Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer NCT07569679Phase 21 site📍 Xi'an Air Force Military Medical University, China · Tests: HAIC, Gemcitabine plus Cisplatin, Adebrelimab, Apatinib A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer NCT07450976Phase 22 sites📍 Beijing📍 Shanghai Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Tests: SHR-A1904 for Injection A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors NCT05592626Phase 1, Phase 219 sites📍 Sacramento📍 Celebration📍 Miami Marengo Therapeutics, Inc. · Tests: STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere) Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma NCT07030140Phase 21 site📍 Jinan Jinbo Yue · Tests: Stereotactic Body Radiotherapy (SBRT), Tislelizumab, Gemcitabine, Cisplatin or Oxaliplatin A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy NCT06793709n/a1 site📍 Tokyo Eisai Co., Ltd. · Tests: No Intervention Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio NCT05655949Phase 21 site📍 Boston Beth Israel Deaconess Medical Center · Tests: Gemcitabine, Cisplatin, Durvalumab, Yttrium-90 Radiation Therapy in Unresectable Gall Bladder Cancer NCT06214572Phase 2, Phase 31 site📍 Mumbai Tata Memorial Centre · Tests: Systemic therapy (Gemcitabine plus Cisplatin), RT, Systemic therapy (Gemcitabine plus oxaliplatin), Systemic therapy (G… PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma NCT05286814Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: Dexamethasone, PDS01ADC, Intera 3000 Hepatic Artery Infusion Pump (HAIP), Floxuridine Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer NCT06274879Phase 24 sites📍 Bern📍 Geneva📍 Lucerne Insel Gruppe AG, University Hospital Bern · Tests: Gemcitabin, Cisplatin and Durvalumab, Biliary Radiofrequency Ablation, Endoscopic Retrograde Cholangio-Pancreatography … Pemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2 Fusion/Rearrangement-Positive Cholangiocarcinoma NCT07786766Phase 21 site📍 Beijing Haitao Zhao, MD · Tests: Pemigatinb, PD-1 inhibitors, Chemotherapy A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) NCT06760819Phase 254 sites📍 Birmingham📍 Duarte📍 Fort Myers Bayer · Tests: BAY2927088 A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) NCT07221253Phase 3183 sites📍 Birmingham📍 Phoenix📍 Tucson AstraZeneca · Tests: Rilvegostomig, Durvalumab, Gemcitabine/Cisplatin Treatment of Non-resectable Bile Duct Cancer with Radiofrequency Ablation or Photodynamic Therapy NCT05551299Phase 420 sites📍 Aachen📍 Augsburg📍 Berlin University of Leipzig · Tests: Photosensitizer, Radiofrequency ablation (RFA) CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers NCT06548412Phase 1, Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Gemcitabine, Cisplatin, Durvalumab, CTX-009 Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC) NCT07433673Phase 21 site📍 New York Columbia University · Tests: Cemiplimab Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients NCT07062263Phase 36 sites📍 Muzaffarpur📍 Mumbai📍 Bhubaneswar Tata Memorial Centre · Tests: Trastuzumab, Chemotherapy Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer NCT05757336Phase 21 site📍 Shanghai Lu Wang, MD, PhD · Tests: Combination of Gemcitabine, Nab-paclitaxel, Sintilimab and Bevacizumab Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer NCT06852287Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: chemotherapy with gemcitabine and oxaliplatin; small molecure TKI lenvatinib; immune-checkpoint inhibitor toripalimab. Repeated Endobiliary Radiofrequency Ablation Plus Durvalumab, Gemcitabine, and Cisplatin for Unresectable Extrahepatic Cholangiocarcinoma NCT07235007NA8 sites📍 Aichi📍 Aichi📍 Aichi Aichi Medical University · Tests: Endobiliary Radiofrequency Ablation (EB-RFA), Plastic Biliary Stent Liver Transplantation for Non-resectable Perihilar Cholangiocarcinoma NCT04993131NA1 site📍 Oslo Oslo University Hospital · Tests: Liver transplant Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy NCT07506057Phase 21 site📍 Shenyang Xiujuan Qu · Tests: Trastuzumab+Serplulimab Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC NCT05733598Phase 212 sites📍 Beverly Hills📍 La Jolla📍 Miami Replimune, Inc. · Tests: RP2, Bevacizumab, Atezolizumab, Durvalumab, RP2 Monotherapy Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer NCT07641036Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: EB-HC01 dual-target CARNK cells, Fludarabine, Cyclophosphamide
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy